STOCK TITAN
  1. Home
  2. Sec-filings
  3. NUVL
  4. [Form 4] Nuvalent, Inc. Insider Trading Activity

[Form 4] Nuvalent, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock NUVL logo
Nuvalent, Inc.

NASDAQ:NUVL

NUVL Rankings

#1737 Ranked by Market Cap
N/A Ranked by Dividends

NUVL Latest News

Jun 24, 2025
Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Jun 23, 2025
Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib
Jun 18, 2025
Nuvalent Appoints Christy Oliger to Board of Directors
May 8, 2025
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results
Apr 29, 2025
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

NUVL Latest SEC Filings

Jul 17, 2025
[SCHEDULE 13G] Nuvalent, Inc. SEC Filing
Jul 17, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Jul 15, 2025
[144] Nuvalent, Inc. SEC Filing
Jul 11, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Jul 9, 2025
[144] Nuvalent, Inc. SEC Filing

NUVL Stock Data

5.85B
62.83M
2.9%
108.09%
7.75%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE